



POWERSVISION



POWERSVISION

Corporate Presentation

CONFIDENTIAL



POWERSVISION[®]



“Fluid controlled accommodating intraocular lenses (IOL’s) to restore the vision of youth”



Company Highlights

- **Proprietary FluidVision™ accommodating IOL**
- **Dramatic improvement over current technology**
- **Early human experience very positive**
- **Strong IP position**
- **Multi-billion dollar market potential**
- **Experienced management team**
- **Top advisory team**

The PowerVision Approach

- Utilizes natural muscular accommodating forces in the eye to move fluids in the FluidVision IOL
- Results in shape change, like the natural lens... creates accommodative range of ~10 diopters



- For comparison, best commercially available competitive technology cannot do >1 diopter

FluidVision Technology Platform

Feature

Benefit

**Fluidic
Control**



**Small Natural
Movements Can
Be Harnessed**

**Shape
Change**



**Large
Accommodative
Range Possible**

**Index
Matching**




**Inner Workings
of Lens
Disappear**


Accomplishments to Date

- **Developed implantable device and advanced our device design to the second generation**
- **Proved technology works in a blind eye model in addition to extensive bench and animal testing**
- **Nearing sighted eyes**
- **Built a great team of engineers and scientists and critical infrastructure to support them**
- **Established a world-class medical and scientific advisory team**
- **Have created strong IP position through our own issued patents as well as licensing deals**

Implantable Product Design



**BODY MADE OF
NOVEL ACRYLIC
MATERIAL**



**FLUID IS
SIICONE OIL**



First in Man - Results

Early Clinical Experience With PowerVision's FluidVision™ Accommodating IOL

ASCRS, April 2008

Polla Roux MD, Louis Nichamin MD



Accommodative Movement in 1st Month

Patient#	Maximum Observed (sag change microns)
1	70
2	50
3	70
4	110
5	100


Results (cont.)

- High accommodative movement maintained at month 3 follow up
- Movement correlates to 5-8D accommodative response in current lens design

- We put a non-optical device in blind eyes; stimulated accommodation and measured movement
- Showed potential for 5-10 diopters of accommodation

PowerVision Expects to be the Best

KEY ACCOMMODATING IOL DEVICES

Company	Mimics Human Accommodation	Keeps Surgeon Procedure Same	Diopter Range
	Yes <ul style="list-style-type: none"> • Lens changes shape like human eye 	Yes <ul style="list-style-type: none"> • No change 	~10
<i>eyeonics/ B&L</i>	No <ul style="list-style-type: none"> • Lens moves forwards or backwards 	Yes <ul style="list-style-type: none"> • No change 	~1
<i>Visiogen/ AMO</i>	No <ul style="list-style-type: none"> • Two lenses move in/out with respect to each other 	Yes <ul style="list-style-type: none"> • No change 	~2
<i>NuLens</i>	No <ul style="list-style-type: none"> • Lens changes shape like bird eye* • <u>Reverse accommodation</u># 	No <ul style="list-style-type: none"> • Sulcus fixated • Pointed anchors in sulcus 	~10

* Source: Cataract Surgery Today, January/February 2008, Ben-Nun, J. (NuLens Inventor)

When individual desires to see near, device adjusts to see far instead (and vice versa) due to device design



Intellectual Property

- **Filed over 30 US and foreign patent applications covering technology**
- **10 issued/allowed patents licensed or owned by PowerVision**
- **Broad coverage of fluid-based IOL's**
- **Broad license and license rights to related IOL technology as well**

Key Advisors

- **Sam Masket, M.D.**
- **Louis (Skip) Nichamin, M.D.**
- **Steve Turner, M.D.**
- **Liliana Werner, M.D., Ph.D.**
- **Terry Kim, M.D.**
- **Ralph Chu, M.D.**
- **Adrian Glasser, Ph.D.**

Management Team and Board

- **Barry Cheskin***, President & CEO and Co-Founder
- **Matt Frinzi***, Chief Business Officer and Founder
- **Ari Zak, Esq.**, Senior Vice President, Clinical, Regulatory and Quality and Corporate Counsel
- **Bryan Flaherty, PhD**, Vice President, R&D
- **Damion Wicker***, Panorama Capital
- **Mike Carusi***, ATV
- **Nathan Every***, Frazier Healthcare Ventures
- **Jim McCollum***, Independent

* Board of Directors

Financing/Milestones

- To date we have raised approximately \$9MM in Series A, just over \$20MM in Series B
- We expect to be raising additional funds in 2010



Disclaimer/Confidentiality

This document contains confidential and/or proprietary information regarding the business and technical affairs of PowerVision Inc. (“PowerVision” or “the Company”). Distribution to any person other than the intended recipient and those persons retained to advise him or her with respect to this information is unauthorized. Any duplication of this document in part or in whole is strictly forbidden. The information provided herein has been prepared in good faith by the Company and does not, to the Company’s knowledge, contain any untrue statement of a material fact, except that with respect to any financial projections or market size assessments, the Company represents only that such projections or assessments were prepared in good faith and that the Company believes there is a reasonable basis for such projections. No investment decisions should be made on the basis of this document. This document does not constitute an offer to sell securities. Please return this original document to PowerVision on request.